Cyclophosphamide or rituximab therapy has been reported to reduce anti-IFN-γ autoAbs titers effectively; therefore, they might be an alternative treatment for autoAbs-positive patients with a refractory opportunistic infection, such as disseminated NTM infection (37–40). Here, IFNG is linked to Opportunistic infection.